Medicalgorithmics EV/Revenue
The EV/Revenue (Enterprise Value to Revenue) of Medicalgorithmics (MDG.WA) as of Sep 2, 2026 is 13.78. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 7.16 — a change of 92.38% (higher).
Get this data via API
Financial Data API
EV/Revenue
13.78
YoY
92.38%
Last updated:
The Medicalgorithmics EV/Revenue history
3 Years
10 Years
25 Years
Max
| YEAR | EV/Revenue | YoY |
|---|---|---|
| 13.78 | +92.38% | |
| 7.16 | +44.17% | |
| 4.97 | -30.43% | |
| 7.14 | +126.88% | |
| 3.15 | +53.01% | |
| 2.06 | +24.84% | |
| 1.65 | -8.02% | |
| 1.79 | -35.69% | |
| 2.79 | -53.13% | |
| 5.94 | -41.90% | |
| 10.23 | — |
Medicalgorithmics Stock analysis
Frequently Asked Questions about Medicalgorithmics stock
EV/Revenue (Enterprise Value to Revenue) of Medicalgorithmics is 13.78 in 2026.
EV/Revenue (Enterprise Value to Revenue) of Medicalgorithmics changed from 7.16 to 13.78, representing a 92.38% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) Medicalgorithmics since 2006 – with annual values, charts, and detailed analysis.
The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.
To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).
A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s Medicalgorithmics with sector peers and the industry average to assess whether it is attractive.
Valuation — Medicalgorithmics
All Key Metrics — Medicalgorithmics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth